Related Experiment Video
Updated: May 2, 2026
Comparative Lesions Analysis Through a Targeted Sequencing Approach
Published on: November 5, 2019
Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing
David G McFadden1, Thales Papagiannakopoulos1, Amaro Taylor-Weiner2
1Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
Abstract:
Small cell lung carcinoma (SCLC) is a highly lethal, smoking-associated cancer with few known targetable genetic alterations. Using genome sequencing, we characterized the somatic evolution of a genetically engineered mouse model (GEMM) of SCLC initiated by loss of Trp53 and Rb1. We identified alterations in DNA copy number and complex genomic rearrangements and demonstrated a low somatic point mutation frequency in the absence of tobacco mutagens. Alterations targeting the tumor suppressor Pten occurred in the majority of murine SCLC studied, and engineered Pten deletion accelerated murine SCLC and abrogated loss of Chr19 in Trp53; Rb1; Pten compound mutant tumors. Finally, we found evidence for polyclonal and sequential metastatic spread of murine SCLC by comparative sequencing of families of related primary tumors and metastases. We propose a temporal model of SCLC tumorigenesis with implications for human SCLC therapeutics and the nature of cancer-genome evolution in GEMMs.
Insights
Small cell lung carcinoma (SCLC) research reveals key genetic drivers and metastatic patterns in a mouse model. Understanding these SCLC evolution mechanisms may inform human cancer therapeutics.
Area of Science:
- Oncology
- Genomics
- Cancer Biology
Background:
- Small cell lung carcinoma (SCLC) is an aggressive cancer with limited therapeutic targets.
- Smoking is a major risk factor for SCLC.
- Genetic alterations driving SCLC remain incompletely understood.
Purpose of the Study:
- To characterize the somatic evolution of SCLC using a genetically engineered mouse model (GEMM).
- To identify genetic alterations and genomic instability in SCLC development.
- To investigate the metastatic process in SCLC.
Main Methods:
- Genome sequencing of a Trp53 and Rb1 deficient GEMM of SCLC.
- Analysis of DNA copy number alterations and complex genomic rearrangements.
- Comparative sequencing of primary tumors and metastases.
Main Results:
- Identified significant DNA copy number alterations and complex genomic rearrangements.
- Observed a low somatic point mutation frequency in the absence of tobacco mutagens.
- Found frequent alterations targeting the tumor suppressor Pten, which accelerated SCLC and affected chromosomal instability.
- Provided evidence for polyclonal and sequential metastatic spread.
Conclusions:
- Proposed a temporal model for SCLC tumorigenesis based on GEMM findings.
- Highlighted the role of Pten alterations in SCLC progression.
- Suggested implications for human SCLC therapeutics and understanding cancer-genome evolution in mouse models.
More Related Videos
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
11:50Genome-Wide Mapping of Histone Modifications and Transcription Factor Binding Sites in Neuroendocrine Small Cell Lung Cancer Cell Lines Using CUT&RUN
Published on: April 3, 2026